(NASDAQ: KPTI) Karyopharm Therapeutics's forecast annual revenue growth rate of 19.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.08%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.39%.
Karyopharm Therapeutics's revenue in 2025 is $142,126,000.On average, 1 Wall Street analysts forecast KPTI's revenue for 2025 to be $1,291,665,648, with the lowest KPTI revenue forecast at $1,291,665,648, and the highest KPTI revenue forecast at $1,291,665,648. On average, 3 Wall Street analysts forecast KPTI's revenue for 2026 to be $1,471,202,853, with the lowest KPTI revenue forecast at $1,339,185,120, and the highest KPTI revenue forecast at $1,629,831,491.
In 2027, KPTI is forecast to generate $2,110,210,153 in revenue, with the lowest revenue forecast at $2,110,210,153 and the highest revenue forecast at $2,110,210,153.